Related Experiment Video
Updated: Sep 8, 2025
Lateral Chronic Cranial Window Preparation Enables In Vivo Observation Following Distal Middle Cerebral Artery Occlusion in Mice
Published on: December 29, 2016
The molecular mechanisms and therapeutic implications of PANoptosis in ischemic diseases
Jiangpeng Wu1, Xunkai Wang1, Jin Peng1
1Key Laboratory of Emergency and Trauma of the Ministry of Education, Department of Interventional Radiology and Vascular Surgery, First Affiliated Hospital of Hainan Medical University, Hainan Medical University, 31 Longhua Road, Longhua District, Haikou City, Hainan Province, China.
Abstract:
The singular forms of programmed cell death (PCD), including pyroptosis, apoptosis, and necroptosis, are inadequate for comprehensively elucidating the complex pathological mechanisms underlying ischemic diseases. PANoptosis is a unique lytic, innate immune, and inflammatory cell death pathway, initiated by innate immune sensors and driven by caspases and RIPKs through PANoptosome complexes. In diseases like cerebral ischemia, retinal ischemia, myocardial ischemia, renal ischemia, and spinal cord ischemia, targeting key regulatory factors of PANoptosis can help mitigate tissue damage. Therefore, the therapeutic potential of PANoptosis in ischemic diseases-from molecular mechanisms to clinical applications-merits further investigation. However, effectively regulating PANoptosis to achieve therapeutic outcomes remains a critical scientific challenge that must be addressed. This review focuses on the molecular mechanisms of PANoptosis in ischemic diseases and its potential therapeutic implications, aiming to provide new insights and a theoretical foundation for precision treatment in these conditions.
Insights
Programmed cell death (PCD) pathways like pyroptosis, apoptosis, and necroptosis are insufficient for understanding ischemic diseases. PANoptosis, a novel cell death pathway, offers therapeutic potential by targeting its regulatory factors to mitigate tissue damage.
Area of Science:
- Immunology
- Cell Biology
- Pathology
Background:
- Single programmed cell death (PCD) pathways (pyroptosis, apoptosis, necroptosis) inadequately explain ischemic disease pathology.
- PANoptosis is a newly identified lytic, inflammatory cell death pathway crucial in innate immunity.
- PANoptosis involves innate immune sensors, caspases, RIPKs, and PANoptosome complexes.
Purpose of the Study:
- To review the molecular mechanisms of PANoptosis in various ischemic diseases.
- To explore the therapeutic potential of targeting PANoptosis for treating ischemic conditions.
- To provide insights for precision medicine approaches in ischemic diseases.
Main Methods:
- Literature review focusing on PANoptosis.
- Analysis of molecular mechanisms in PANoptosis.
- Discussion of therapeutic strategies targeting PANoptosis.
Main Results:
- PANoptosis plays a significant role in cerebral, retinal, myocardial, renal, and spinal cord ischemia.
- Targeting key regulatory factors of PANoptosis can mitigate tissue damage in ischemic diseases.
- Understanding PANoptosis offers a novel therapeutic avenue for ischemic conditions.
Conclusions:
- PANoptosis represents a promising therapeutic target for ischemic diseases.
- Further research is needed to overcome challenges in regulating PANoptosis for clinical benefit.
- This review provides a foundation for developing precision treatments for ischemic diseases based on PANoptosis.
